IN2012DN00999A - - Google Patents

Info

Publication number
IN2012DN00999A
IN2012DN00999A IN999DEN2012A IN2012DN00999A IN 2012DN00999 A IN2012DN00999 A IN 2012DN00999A IN 999DEN2012 A IN999DEN2012 A IN 999DEN2012A IN 2012DN00999 A IN2012DN00999 A IN 2012DN00999A
Authority
IN
India
Prior art keywords
solvates
useful
formula
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
Other languages
English (en)
Inventor
James A Henderson
John Maxwell
Louis Vaillancourt
Mark Morris
Jr Ronald Grey
Simon Giroux
Laval Chan Chun Kong
Sanjoy Kumar Das
Bingcan Liu
Carl Poisson
Caroline Cadilhac
Monica Bubenik
T Jagadeeswar Reddy
Guy Falardeau
Constantin Yannopoulos
Jian Wang
Oswy Z Pereira
Youssef L Bennani
Albert C Pierce
Govinda Rao Bhisetti
Kevin M Cottrell
Valerie Marone
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IN2012DN00999A publication Critical patent/IN2012DN00999A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052Val-amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
IN999DEN2012 2009-07-16 2010-07-16 IN2012DN00999A (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22615209P 2009-07-16 2009-07-16
US31701710P 2010-03-24 2010-03-24
PCT/US2010/042340 WO2011009084A2 (en) 2009-07-16 2010-07-16 Benzimidazole analogues for the treatment or prevention of flavivirus infections

Publications (1)

Publication Number Publication Date
IN2012DN00999A true IN2012DN00999A (sv) 2015-04-10

Family

ID=43385139

Family Applications (1)

Application Number Title Priority Date Filing Date
IN999DEN2012 IN2012DN00999A (sv) 2009-07-16 2010-07-16

Country Status (10)

Country Link
US (3) US8354419B2 (sv)
EP (1) EP2454254A2 (sv)
JP (1) JP2012533569A (sv)
CN (1) CN102656160A (sv)
AU (1) AU2010274001A1 (sv)
CA (1) CA2767887A1 (sv)
IL (1) IL217503A0 (sv)
IN (1) IN2012DN00999A (sv)
MX (1) MX2012000695A (sv)
WO (1) WO2011009084A2 (sv)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
JP2012513409A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
CN109020961A (zh) 2009-05-13 2018-12-18 吉利德制药有限责任公司 抗病毒化合物
JP2012528194A (ja) * 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション C型肝炎などの疾患を処置するための3つの整列型アリール部分で構成された抗菌性化合物
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
TWI469780B (zh) 2009-06-11 2015-01-21 Abbvie Bahamas Ltd 抗病毒化合物
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
CN102656160A (zh) * 2009-07-16 2012-09-05 顶点制药公司 用于治疗或预防黄病毒感染的苯并咪唑类似物
CN102482260A (zh) * 2009-09-03 2012-05-30 泰博特克药品公司 双-苯并咪唑衍生物
PE20120993A1 (es) 2009-09-04 2012-08-22 Janssen Pharmaceuticals Inc Derivados bifenilicos como antivirales
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR079528A1 (es) * 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20120107529A (ko) 2010-01-25 2012-10-02 이난타 파마슈티칼스, 인코포레이티드 C형 간염 바이러스 억제제
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
AU2010347272A1 (en) * 2010-03-04 2012-09-20 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of HCV replication
WO2011119858A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119853A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011153396A1 (en) 2010-06-04 2011-12-08 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EP2603080A4 (en) 2010-08-12 2014-01-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US20150158909A1 (en) * 2010-12-15 2015-06-11 Abbevie Inc. Anti-viral compounds
CN103384664A (zh) * 2010-12-16 2013-11-06 Abbvie公司 抗病毒化合物
WO2012087976A2 (en) * 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6240063B2 (ja) 2011-04-28 2017-11-29 ザ ブロード インスティテュート, インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012158861A2 (en) 2011-05-18 2012-11-22 Enanta Pharmaceuticals, Inc. Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
US20150126747A1 (en) * 2011-05-26 2015-05-07 Abbvie Inc. Anti-viral compounds
US20150105548A1 (en) * 2011-05-26 2015-04-16 Abbvie Inc Anti-viral compounds
US9303061B2 (en) 2011-07-09 2016-04-05 Sunshine Luke Pharma Co., Ltd. Spiro compounds as Hepatitis C virus inhibitors
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
AU2012360905B2 (en) 2011-12-28 2017-04-27 Janssen Sciences Ireland Uc Hetero-bicyclic derivatives as HCV inhibitors
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6337255B2 (ja) 2012-07-27 2018-06-06 ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. ヒストンデアセチラーゼの阻害剤
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US9802949B2 (en) 2012-11-29 2017-10-31 Sunshine Lake Pharma Co., Ltd. Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
US9416139B2 (en) 2012-11-29 2016-08-16 Sunshine Lake Pharma Co., Ltd. Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
WO2014100438A1 (en) 2012-12-20 2014-06-26 The Broad Institute, Inc. Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors
SI2950786T1 (sl) 2013-01-31 2020-03-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US9738629B2 (en) 2014-01-23 2017-08-22 Sunshine Lake Pharma Co., Ltd. Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
JP2016079168A (ja) * 2014-10-17 2016-05-16 塩野義製薬株式会社 9員縮合環誘導体
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11096927B2 (en) 2018-12-19 2021-08-24 Florida State University Research Foundation, Inc. Anti-flavivirus compounds and methods of use
US20230312542A1 (en) * 2020-03-31 2023-10-05 Mitsubishi Tanabe Pharma Corporation Hydroxypyrrolidine derivative and medicinal application thereof
CN117460734A (zh) 2021-05-21 2024-01-26 吉利德科学公司 作为寨卡病毒抑制剂的五环衍生物

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014852A2 (en) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones as inhibitors of hcv replication
DK1718608T3 (da) * 2004-02-20 2013-10-14 Boehringer Ingelheim Int Virale polymeraseinhibitorer
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
EP2250163B1 (en) 2008-02-12 2012-03-28 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2010008863A (es) 2008-02-13 2010-09-07 Bristol Myers Squibb Co Imidazolil-bifenil-imidazoles como inhibidores del virus de la hepatisis c.
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5268532B2 (ja) 2008-09-30 2013-08-21 株式会社日立ハイテクノロジーズ 試料計測方法、及び計測装置
JP5100595B2 (ja) 2008-09-30 2012-12-19 シャープ株式会社 Av機器、サーバ、av機器の操作システムおよびav機器の操作用プログラム
JP5225240B2 (ja) 2008-10-01 2013-07-03 住友ゴム工業株式会社 タイヤ用ゴム組成物及びタイヤ
EP2373167A4 (en) 2008-12-03 2012-07-25 Presidio Pharmaceuticals Inc INHIBITORS OF HEPATITIS C VIRUS TYPE NS5A
EA024853B1 (ru) 2008-12-03 2016-10-31 Пресидио Фармасьютикалс, Инк. Ингибиторы ns5a вгс
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US20120040977A1 (en) 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
KR101411889B1 (ko) 2009-02-27 2014-06-27 이난타 파마슈티칼스, 인코포레이티드 C형 간염 바이러스 억제제
KR20110131312A (ko) 2009-03-27 2011-12-06 프레시디오 파마슈티칼스, 인코포레이티드 융합된 고리 c형 간염 억제제
ME02418B (me) 2009-03-27 2016-09-20 Merck Sharp & Dohme Inhibitori replikacije virusa hepatitisa c
CA2756255A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 C型肝炎病毒抑制劑
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
CN102414199B (zh) 2009-04-24 2014-03-05 泰博特克药品公司 二芳基醚
JP2012526834A (ja) 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
CN109020961A (zh) 2009-05-13 2018-12-18 吉利德制药有限责任公司 抗病毒化合物
JP2012528195A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション C型肝炎などの疾患を処置するための3つの結合アリール部分で構成された抗菌性化合物
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI469780B (zh) 2009-06-11 2015-01-21 Abbvie Bahamas Ltd 抗病毒化合物
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
CN102656160A (zh) * 2009-07-16 2012-09-05 顶点制药公司 用于治疗或预防黄病毒感染的苯并咪唑类似物
PE20120993A1 (es) 2009-09-04 2012-08-22 Janssen Pharmaceuticals Inc Derivados bifenilicos como antivirales
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR079528A1 (es) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
KR20120107529A (ko) 2010-01-25 2012-10-02 이난타 파마슈티칼스, 인코포레이티드 C형 간염 바이러스 억제제
AU2010347272A1 (en) 2010-03-04 2012-09-20 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as inhibitors of HCV replication
BR112012022125A2 (pt) 2010-03-09 2016-11-01 Merck Sharp & Dhme Corp composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
WO2011119858A1 (en) * 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
US9127021B2 (en) 2010-04-09 2015-09-08 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
US20130296311A1 (en) 2010-05-28 2013-11-07 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2011153396A1 (en) 2010-06-04 2011-12-08 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US20130310427A1 (en) 2010-06-09 2013-11-21 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
EP2601188B1 (en) 2010-08-04 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2603080A4 (en) 2010-08-12 2014-01-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
EP2619195A1 (en) 2010-09-24 2013-07-31 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2012041227A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds for treating hepatitis c viral infection
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
MX2013003631A (es) 2010-09-29 2013-10-01 Merck Sharp & Dohme Derivados de indol tetraciclicos y sus métodos para el tratamiento de enfermedades virales.
WO2012040923A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
WO2012040924A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
AU2011320696B2 (en) 2010-10-26 2016-07-21 Presidio Pharmaceuticals, Inc. Inhibitors of Hepatitis C Virus
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
JP6198721B2 (ja) 2011-05-27 2017-09-20 アキリオン ファーマシューティカルズ,インコーポレーテッド Hcv感染症を治療するのに有用な置換されたアリファン、シクロファン、ヘテラファン、ヘテロファン、ヘテロ−ヘテラファンおよびメタロセン

Also Published As

Publication number Publication date
JP2012533569A (ja) 2012-12-27
CN102656160A (zh) 2012-09-05
AU2010274001A1 (en) 2012-02-23
US20130157997A1 (en) 2013-06-20
CA2767887A1 (en) 2011-01-20
US20110172238A1 (en) 2011-07-14
US8354419B2 (en) 2013-01-15
IL217503A0 (en) 2012-03-01
US8765731B2 (en) 2014-07-01
WO2011009084A2 (en) 2011-01-20
WO2011009084A3 (en) 2011-04-28
MX2012000695A (es) 2012-06-12
EP2454254A2 (en) 2012-05-23
US20140243257A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
IN2012DN00999A (sv)
MX2012007420A (es) Analogos para el tratamiento o prevencion de infecciones de flavivirus.
MX2012010918A (es) Analogos para el tratamiento o prevencion de infecciones por flavivirus.
HK1166788A1 (sv)
SG178952A1 (en) Chemical compounds
HK1112910A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
IN2012DN01855A (sv)
EP2507232A4 (en) PROLINE DERIVATIVES
EP2041159B8 (en) Macrocyclic compounds as antiviral agents
MX2009012418A (es) Derivados de quinazolin-oxima como inhibidores de hsp90.
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
MX2011011136A (es) Eteres diarilicos.
MX351589B (es) Antibioticos de oxazolidinona.
MX2013006475A (es) Inhibidores macrociclicos de virus flaviviridae.
MX2010004623A (es) Compuestos heterociclicos antiviricos.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
MX2012003170A (es) Compuestos heterociclicos antivirales.
TNSN08407A1 (en) Organic compounds
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
TN2010000212A1 (en) Inhibitors of human immunodeficiency virus replication
MX2012006026A (es) Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
MX2009012222A (es) Dihidroquinonas y dihidronaftiridinas como inhibidores de las quinasas c-jun-n-terminales.
NZ600817A (en) Inhibitors of flaviviridae viruses
MX2010002461A (es) (carboxilalquilenfenil)feniloxamidas, metodo para su produccion y uso de las mismas como medicamento.
MX2012008221A (es) Inhibidores de virus flaviviridae.